

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company" or "Avita Medical")
ABN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	9 September 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	7 November 2022 (but with retrospective effect from 28 September 2022)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>634,602 CDIs in the Company quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in the Company ("Shares"))</p> <p>102,579 Shares</p> <p>83,360 unquoted RSUs in the Company</p> <p>55,200 unquoted Options in the Company</p> <p>Dr Perry also held 15,000,000 unquoted options in Avita Medical Pty Ltd ("Avita Australia"), being a wholly owned subsidiary of the Company (consolidation equivalent = 150,000 unquoted Options in the Company) The unquoted options held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued Shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p>
<p>Class</p>	<p>As above</p>
<p>Number acquired</p>	<p>Nil</p>
<p>Number disposed</p>	<p>59,560 unquoted RSUs in the Company; and</p> <p>34,500 unquoted Options in the Company exercisable at \$12.18 per Option</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil (see nature of change section below)</p>
<p>No. of securities held after change</p>	<p>634,602 CDIs in the Company quoted on ASX (representing beneficial ownership of 126,920 Shares)</p> <p>102,579 Shares</p> <p>23,800 unquoted RSUs in the Company</p> <p>20,700 unquoted Options in the Company</p> <p>Dr Perry also holds 15,000,000 unquoted options in Avita Australia, being a wholly owned subsidiary of the Company (consolidation equivalent = 150,000 unquoted Options in the Company). The unquoted options held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued Shares in the Company (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in the Company's pre-quotations disclosure released to the market on 24 June 2020.</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Forfeiture of unquoted RSU's and expiry of unquoted Options in the Company due to the cessation of Dr Perry as Chief Executive Officer of the Company on 28 September 2022.</p>
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/a
Nature of interest	N/a
Name of registered holder (if issued securities)	N/a
Date of change	N/a
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/a
Interest acquired	N/a
Interest disposed	N/a
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/a
Interest after change	N/a

Part 3 – +Closed period

<p>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</p>	No
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	N/a
<p>If prior written clearance was provided, on what date was this provided?</p>	N/a

+ See chapter 19 for defined terms.

For personal use only